Design Therapeutics (DSGN) Current Assets (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Current Assets of $212.0 million for Q2 2026, down 3.54% year-over-year from $219.8 million in Q2 2025, and down 6.62% on a QoQ basis from $227.0 million in Q1 2026.
Design Therapeutics (DSGN) Current Assets (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Current Assets for 7 years, with the latest figure at $212.0 million in Q2 2026.
- Current Assets for Q2 2026 came in at $212.0 million, down 3.54% year-over-year; the trailing twelve-month figure through Jun 2026 was $212.0 million (down 3.54% YoY), and the FY2025 annual result was $223.8 million, down 9.78% from the prior year.
- Current Assets declined to $212.0 million in Q2 2026, from $227.0 million in the prior quarter.
- Over five years, Current Assets peaked at $373.9 million in Q1 2022 and troughed at $209.0 million in Q3 2025.
- A 5-year average of $277.4 million and a median of $269.4 million in 2024 frame the typical range for Current Assets.
- The widest annual swing landed in 2025, when Current Assets decreased 18.74%; it then fell 2.82% in 2026.
- A 5-year view of Current Assets shows it stood at $335.1 million in 2022, then fell by 15.08% to $284.6 million in 2023, then retreated by 12.84% to $248.0 million in 2024, then dropped by 9.78% to $223.8 million in 2025, then declined by 5.26% to $212.0 million in 2026.
- Per Business Quant data, the three most recent Current Assets figures were $212.0 million in Q2 2026, $227.0 million in Q1 2026, and $223.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 212.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 212.01 Mn |
| Mar 31, 2026 | 227.05 Mn |
| Dec 31, 2025 | 223.78 Mn |
| Sep 30, 2025 | 209.03 Mn |
| Jun 30, 2025 | 219.79 Mn |
| Mar 31, 2025 | 233.64 Mn |
| Dec 31, 2024 | 248.04 Mn |
| Sep 30, 2024 | 257.24 Mn |
| Jun 30, 2024 | 264.84 Mn |
| Mar 31, 2024 | 273.89 Mn |
| Dec 31, 2023 | 284.58 Mn |
| Sep 30, 2023 | 294.54 Mn |
| Jun 30, 2023 | 306.05 Mn |
| Mar 31, 2023 | 318.94 Mn |
| Dec 31, 2022 | 335.12 Mn |
| Sep 30, 2022 | 348.49 Mn |
| Jun 30, 2022 | 361.72 Mn |
| Mar 31, 2022 | 373.87 Mn |
| Dec 31, 2021 | 385.44 Mn |
| Sep 30, 2021 | 395.29 Mn |